USA flag logo/image

An Official Website of the United States Government

THE PROPOSED STUDY TARGETS THE WELL-VASCULARIZED AND REFRACTORY CLASS OF…

Award Information

Agency:
Department of Health and Human Services 		Branch:
N/A 		Award ID:
5298 		Program Year/Program:
1986 / SBIR
Agency Tracking Number:
5298 		Solicitation Year:
N/A 		Solicitation Topic Code:
N/A 		Solicitation Number:
N/A
Small Business Information
Angiogen, Inc.
Angiogen, Inc. 4050 Sorrento Valley Blvd, Ste O San Diego, CA 92121 0142
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 1986
Title: THE PROPOSED STUDY TARGETS THE WELL-VASCULARIZED AND REFRACTORY CLASS OF CENTRAL NERVOUS SYSTEM (CNS) TUMORS FOR THE DEVELOPMENT OF NOVEL METHODS FOR DETECTING THE PRESENCE AND QUANTITATING AMOUNTS OF SPECIFIC TUMOR-PRODUCED ANGIO- GENESIS FACTORS (AF).
Agency: HHS
Contract: N/A
Award Amount: $50,000.00
 

Abstract:

THE PROPOSED STUDY TARGETS THE WELL-VASCULARIZED AND REFRACTORY CLASS OF CENTRAL NERVOUS SYSTEM (CNS) TUMORS FOR THE DEVELOPMENT OF NOVEL METHODS FOR DETECTING THE PRESENCE AND QUANTITATING AMOUNTS OF SPECIFIC TUMOR-PRODUCED ANGIO- GENESIS FACTORS (AF). CELL HOMOGENATES AND CONDITION MEDIA FROM CELL CULTURES OF ANIMAL AND HUMAN CNS TUMORS WILL BE EMPLOYED IN THE PHASE I STUDIES. TWO KINDS OF AF MOLECULES WILL BE SOUGHT BY THE SCREENING STUDIES: (1) LOW MOLECULAR WEIGHT (MW) FACTORS (<1000 DALTONS) AND (2) HIGHER MW POLYPEPTIDES (>16,000D). FRACTIONATION OF THE TUMOR CELL- DERIVED SAMPLES WILL BE ACCOMPLISHED USING ULTRAFILTRATION OR EXTRACTION METHODS AND, IF NECESSARY, CHROMATOGRAPHIC METHODS, THE ACTIVITIES OF THESE MATERIALS WILL BE DETER- MINED USING AN ANGIOGENESIS (CAM) ASSAY AS WELL AS TWO IN VITRO ASSAYS THAT CORRESPOND TO SEPARATE STEPS OF THE ANGIOGENIC PROCESS (VASCULAR ENDOTHELIAL CELL(EC) PROLIFERA-TION AND MIGRATION). IMMUNOASSAYS THAT ARE BASED ON THE REPORTED PROCEDURES FOR A LOW MW AF AND POLYPEPTIDE AF WILL BE DEVELOPED FOR DETECTING ACTIVE MOLECULES IN THESE CNS TUMOR PREPARATIONS. THE PROTOCOLS FROM THESE STUDIES WILL BE USED IN PHASE II TO MEASURE AF CONTENT IN TISSUE AND CEREBROSPINAL FLUID (CSF) SAMPLES FROM CNS CANCER PATIENTS.

Principal Investigator:

Allan fenselau
PRINCIPAL INVESTIGATOR
3016676880

Business Contact:

Small Business Information at Submission:

Angiogen
107 Lakefront Drive Hunt Valley, MD 21030

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No